FastForward Innovations Ltd (LON:FFWD) said its portfolio firm, Juvenescence has formed a joint venture with biotech firm G3 Therapeutics, called Juvenomics, which will focus on developing medicines to combat ageing and age-related diseases.
The company, which owns a 0.63% stake in Juvenescence, said Juvenomics is built on Juvenescence’s machine learning platforms in combination with G3’s proprietary, multi-omic biological dataset, consisting of trillions of proprietary datapoints collected in the GLOBAL Clinical Study of over 7,500 patients.
Juvenomics has also appointed David Roblin, the former president of research & development at Summit Therapeutics PLC (NASDAQ:SMMT), head of anti-infectives at Bayer and head of research in Europe at Pfizer Inc (NYSE:PFE), as its chief operating offer.
"At Juvenescence, we are very excited about this opportunity to work with G3. Since its inception Juvenescence has been at the vanguard of applying data science towards drug discovery and development”, Juvenescence founder and chief executive Gregory Bailey said in a statement.
“The depth of the patient-derived database assembled by G3 is extraordinary and compelling. To have exclusive access to the existing data and the new data that G3 generates going forward for anti-ageing and age-related diseases is a unique opportunity. This data gives us the ability to accelerate discovery and development of therapeutics to modify healthy ageing", Bailey added.
Shares in FastForward were steady at 6p in mid-morning trading on Tuesday.